Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'

Affiliations

Comment

A Arits et al. Br J Dermatol. 2015 Jan.

. 2015 Jan;172(1):11-2.

doi: 10.1111/bjd.13565.

¹ Department of Dermatology, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands. a.arits@MUMC.nl.

No abstract available

Comment on

Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, van Pelt HP, Quaedvlieg PJ, Krekels GA, van Neer PA, Rijzewijk JJ, van Geest AJ, Steijlen PM, Nelemans PJ, Kelleners-Smeets NW. Arits AH, et al. Lancet Oncol. 2013 Jun;14(7):647-54. doi: 10.1016/S1470-2045(13)70143-8. Epub 2013 May 15. Lancet Oncol. 2013. PMID: 23683751 Clinical Trial.
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
Lecluse LL, Spuls PI. Lecluse LL, et al. Br J Dermatol. 2015 Jan;172(1):8-10. doi: 10.1111/bjd.13460. Br J Dermatol. 2015. PMID: 25581584